CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CARE1 project investigates treatment strategies for metastatic clear cell kidney cancer by comparing two immunotherapy approaches. It aims to determine the optimal combination therapy based on patient biomarkers to improve overall survival outcomes.
In 2020, there were an estimated 431 288 new cases of kidney cancer (Renal Cell Carcinoma, RCC) globally with 138 611 cases in Europe, leading to 179 368 deaths worldwide, including 54 054 deaths in Europe (source:
IARC/Globocan).
To define high priority topics in academic research and launch dedicated trials, European RCC academic physicians have gathered into a European initiative – the CARE group.
Systemic therapy for RCC relies on two classes of agents: anti-angiogenic targeted therapy (Vas…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Villejuif
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
France, Rennes Cedex 9
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Essen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE
Spain, Barcelona
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
